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points (p = 0.007) lower pain score than non-duloxetine-treated patients among 
individuals who had any opioid use during the 12-month post-index period. CON-
CLUSIONS: Among similar VA patients with MDD, patients treated with duloxetine 
were associated with lower opioid use than those treated with other antidepressants. 
Among individuals with any opioid use over the 12-month post-index period, duloxetine-
treated patients had better pain scores than non-duloxetine-treated patients.
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OBJECTIVES: Although not approved for use in pediatrics, hydroxyurea has been 
shown to decrease painful vaso-occlusive events and hospitalizations (HU) in children 
with sickle cell disease (SCD), a genetic hematologic disorder primarily affecting 
people of African descent. However, few data exist on the use of HU, and adherence 
to treatment, in real-world settings. This study assessed the extent to which children 
with SCD are adherent with prescribed HU therapy and the association between HU 
adherence and economic outcomes in this population in a real-world setting. 
METHODS: Insurance claims of North Carolina Medicaid program enrollees (June 
1999-August 2008) were analyzed. Inclusion criteria were ≥1 claims with a diagnosis 
for SCD (i.e., ICD-9-CM 282.6, 282.6x), ≥2 HU prescriptions in the year following 
HU initiation, ≤18 years old at the time of HU initiation, and continuous Medicaid 
enrollment for ≥12 months prior to and following HU initiation. Adherence was 
measured using the medication possession ratio (MPR), with MPR > 0.8 considered 
adherent. Multivariable models were estimated to assess the association between HU 
adherence and economic outcomes (e.g., inpatient costs) in the ﬁ rst year of HU therapy. 
RESULTS: A totla of 159 subjects (55% female, mean age [SD] 11.3 [4.4] years) met all 
inclusion criteria. The mean MPR was 0.63, with 41% of subjects adherent. Multivariable 
models revealed that in the year following HU initiation, adherence was associated with 
a reduction in all-cause (-$3.695, p = 0.0003) and SCD-related (-$3.002, P < 0.0001) 
total, inpatient (-$2172, p = 0.001; -$1815, P < 0.0001, respectively), ER (-$314, P < 
0.0001; -$202, p = 0.002, respectively), outpatient (-$951, P < 0.0001; -$541, p = 0.005, 
respectively), and vaso-occlusive event-related (-$3639, P < 0.0001) costs, and an increase 
in all-cause (+$239, p = 0.014) and SCD-related pharmacy (+$198, P < 0.0001) costs. 
CONCLUSIONS: Adherence to HU among pediatric SCD patients may be suboptimal 
and improving adherence to HU therapy among these patients may reduce the eco-
nomic burden of the illness.
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OBJECTIVES: The aim of this study is to determine health care resource utilization 
and direct medical costs in patients treated with intravenous immunoglobulins (IVIGs) 
in Spain in 2009. METHODS: A cost-of-illness analyses was performed to estimate 
direct medical annual costs of patients treated with IVIGs. Prevalence data was 
obtained from the Spanish Primary Immunodeﬁ ciency registry. a semi-structured ques-
tionnaire was used to collect data on health care resource utilization and target popula-
tion distribution. Inpatient and outpatient costs were considered from the perspective 
of the public health care system. Hospital costs considered were ambulatory-, ward-, 
premedication-, drug- and administration costs. All costs referred to 2009. In medical 
practice, IVIG doses depend on a patient’s weight and age. Therefore separate analyses 
were conducted for children and adolescents vs. adults. RESULTS: Patients with 
replacement therapy were estimated to be 4192 (724 children and adolescents vs. 3450 
adults) for 2009. Patients with immunomodulation were estimated to be 1378 (244 
children and adolescents vs. 1134 adults) and patients with an allogeneic bone marrow 
transplantation were estimated at 172 (30 children and adolescents vs. 142 adults ). 
Mean annual costs for children and adolescents were c6283 with Privigen, c6292 with 
Kiovig, c6946 with Flebogamma and c6559 with Octagamocta. For adults estimations 
were c17,078 with Privigen, c17,103 with Kiovig, c18,095 with Flebogamma and 
c17,423 with Octagamocta. CONCLUSIONS: Direct medical costs for IVIGs were 
estimated to be c6.9 million for children and adolescents and c84.8 million for adult 
patients. Drug costs represented 94% of the total direct medical costs. In the context 
of limited health care resources, the choice for a certain IVIG treatment depends on 
individual patient characteristics and cost considerations.
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OBJECTIVES: To explore predictors of duloxetine initiation versus other standard of 
care (SOC) treatments for patients with diabetic peripheral neuropathic pain (DPNP) 
in the Veterans Affairs (VA) health system. Duloxetine was not on the VA national 
drug formulary. METHODS: The electronic medical records from January 2004 to 
December 2008 were requested from the Veterans Integrated Service Network 16 data 
warehouse. All patients selected initiated either duloxetine or SOC (tricyclic antide-
pressants [TCAs], venlafaxine, gabapentin, pregabalin) over the study period, with the 
ﬁ rst dispense date of the index agent as the index date. All patients must have at least 
1 prior DPNP diagnosis (ICD-9-CM: 250.6x or 357.2), but no prior depression (ICD-
9-CM: 296.2, 296.3, 300.4, 309.1, 311.0), ﬁ bromyalgia (ICD-9-CM: 729.1), or 
neuralgia (ICD-9-CM: 729.2) diagnosis. Logistic regressions were used to examine the 
predictors of initiating duloxetine versus SOC controlling for demographics, comor-
bidities, prior pain level, and prior SOC or opioid use. RESULTS: The analytical 
sample included 2675 (215 duloxetine and 2460 SOC) patients. Prior use of gabap-
entin (odds ratio [OR] = 13.66, 95% conﬁ dence interval [CI]: 9.70–19.24, TCAs (OR 
= 5.40, 95% CI: 3.73–7.82), or venlafaxine (OR = 3.67, 95% CI: 1.67–8.06) was 
strongly associated with duloxetine initiation. Patients comorbid with anxiety, cere-
brovascular disease, or substance abuse were 1.08 (95% CI: 1.40–3.08), 0.44 (95% 
CI: 1.01–2.07), and 1.11 (95% CI: 1.10–4.03) times more likely to initiate duloxetine, 
respectively. Prior opioid users were 1.47 (95% CI: 1.02–2.12) times as likely to initi-
ate duloxetine as those with no prior opioid use. Patients with self-reported severe 
pain were 1.66 (95% CI: 1.11–2.50) times as likely to initiate duloxetine as those with 
no reported pain. CONCLUSIONS: DPNP patients in the VA health care system who 
initiated duloxetine appeared to have prior SOC use, more comorbid conditions, prior 
substance abuse or opioid use, and higher pain level.
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OBJECTIVES: To summarise the state of knowledge of the economic impact of SLE 
and to gather information to implement a European study on costs of SLE care. 
METHODS: A systematic review of the literature was undertaken in the ECONLIT, 
EMBASE, Medline and EMBR databases for full papers relating to the objectives. Key 
words included SLE, cost, resource, economic, productivity, absenteeism, employment 
and work disability. Papers were excluded if they were not in English, French, Spanish, 
Italian or German language. RESULTS: Thirty relevant research papers (relating to 
13 different studies) were included. These studies were conducted in Canada, China, 
Germany, UK and US and used retrospective and prospective methods. Data were 
mainly obtained from the hospital care setting over a one-year study period. The main 
resources reported were physician and emergency visits, as well as inpatient hospital 
stays (of which SLE ﬂ ares and infections were the main causes). Annual direct costs 
(converted to December 2009 Euros) ranged from c2,879 (Canada) to c14,873 (US), 
with indirect costs of c1,214 (US/UK/Canada, friction method) to c45,668 (US, labour 
market activity method). Indirect costs accounted for at least 38% of the total costs 
when both market and non-market work was valued. Higher disease activity was 
reported as a predictor of higher direct and indirect costs. Greater damage, more ﬂ ares 
and nephritis were also found to predict higher direct costs whilst worse physical and/
or mental status predicted higher indirect costs. Only one study focussed on the cost 
of ﬂ ares. CONCLUSIONS: SLE is costly for the health care system and workplace. 
However, there is a lack of data on the cost of SLE ﬂ ares and little recent European 
data relating to the cost of SLE care. HGS/GSK funded.
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OBJECTIVES: To quantify the direct costs (hospitalizations and prescription drugs) 
of the caring strategies for the Inﬂ ammatory Bowel Disease (IBD). METHODS: All 
cases of the major types of IBD, Crohn’s disease (CD) and ulcerative colitis (UC), 
occurred in Apulia between 2002 and 2006 were in the study. The patients were 
identiﬁ ed through a record linkage procedure among three different regional health 
databases. Multivariate Poisson regression accounting for over-dispersion was used to 
assess the average annual direct costs per person. Results were reported, separately 
for the two diseases, as Incidence Rate Ratios (IRR) with 95% conﬁ dence intervals. 
RESULTS: The cohort consisted of 2,700 cases of CD and 4902 cases of UC. We 
estimated the average annual costs per person in patients with CD to be equal to 7,153 
Euros for hospitalizations and to c2107 for prescription drugs. In patients with UC 
the average annual costs per person was of c6317 and c2277 for hospitalizations and 
prescription drugs, respectively. Surgical to medical DRGs ratio for both diseases was 
1:5 and the ATC codes relative to intestinal anti-inﬂ ammatory, proton pump inhibi-
tion, anti-inﬂ ammatory/anti-rheumatic and corticosteroids products, represented the 
40% of all prescriptions. Overall, the analyses showed, both for DC and CU, that the 
Charlson Comorbidity Index (CCI) was the only variable associated with the direct 
costs i.e. a signiﬁ cant increase in the costs (p-value < 0.0001) was found according to 
the severity of the CCI. In particular, it was noted that a worse clinical condition 
before disease onset (CCI before index date) was predictive of larger costs especially 
